A Neutral Risk on the Development of New-Onset Diabetes Mellitus (NODM) in Taiwanese Patients with Dyslipidaemia Treated with Fibrates
Table 1
Descriptive characteristics of fibrate prescriptions in the population, 2005–2010.
Characteristics
NODM
No-NODM
Total
-value
%
%
%
Total
145
3.8
3,670
96.2
3,815
100
Age (year, mean ± SD)
0.616
Gender
Female
58
40.00
1,372
37.38
1,430
37.48
0.523
Male
87
60.00
2,298
62.62
2,385
62.52
Drug group
Fenofibrate
104
71.72
2,702
73.62
2,806
73.55
0.611
Gemfibrozil
41
28.28
968
26.38
1,009
26.45
Mean dose
Fenofibrate
0.048
Gemfibrozil
0.198
Differences in continuous variables were analysed using the unpaired student’s t-test. Categorical variables were analysed using by either Fisher’s exact test or the chi-squared test.